Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Eli Lilly's Mounjaro demonstrated superior cardiovascular protection in a head-to-head trial against its older drug Trulicity, reducing major adverse heart events by 8% and all-cause death by 16% in high-risk type 2 diabetes patients. These results, despite a slight initial dip in Lilly shares reflecting high investor expectations, solidify Mounjaro's market dominance as the company's top seller with $11.5 billion in 2023 sales, positioning it for expanded FDA approval by 2026 and intensifying competition within the lucrative GLP-1 market, particularly against Novo Nordisk's cardiovascular indications.

Analysis

Eli Lilly's head-to-head trial results confirm Mounjaro's clinical superiority over its older blockbuster, Trulicity, in the lucrative type 2 diabetes market. Mounjaro demonstrated an 8% greater reduction in major adverse cardiovascular events and a significant 16% lower risk of all-cause mortality, solidifying its best-in-class profile. This data provides a strong rationale for physicians to switch patients from Trulicity, accelerating the sales cannibalization already evident in 2023 figures where Mounjaro's sales of $11.5 billion more than doubled Trulicity's $5.2 billion. The initial 0.5% dip in LLY shares suggests the market had already priced in a positive outcome, with some investors anticipating an even wider superiority margin. The planned FDA submission for an expanded cardiovascular indication, with potential approval in 2026, is a critical future catalyst that will further entrench Mounjaro's market leadership and intensify its competition with Novo Nordisk's rival GLP-1 offerings. While Mounjaro's safety profile was similar to Trulicity's, the higher discontinuation rate due to side effects (13.3% vs. 10.2%) represents a modest but noteworthy factor for patient retention.

Key Decisions for Investors

• The data reinforces a bullish long-term thesis on Eli Lilly, as Mounjaro's demonstrated cardiovascular and mortality benefits are poised to accelerate market share capture from both internal legacy products and external competitors like Novo Nordisk's Ozempic.
• Investors should closely monitor the timeline for Lilly's FDA submission later this year and the subsequent review, as the anticipated 2026 approval for a cardiovascular indication represents a key catalyst for expanding insurance coverage and solidifying revenue forecasts.
• The muted stock reaction to positive news indicates that extremely high expectations are priced into LLY, suggesting that future trial readouts must show overwhelming superiority to drive significant upside, and new positions should consider the elevated valuation.
• While the results favor Lilly, it is crucial to continue tracking the competitive landscape, particularly Novo Nordisk's progress in securing expanded labels for Wegovy and Ozempic, as this remains the primary risk factor to Lilly's dominance in the GLP-1 market.